Bleakley Financial Group LLC Sells 9,086 Shares of Novo Nordisk A/S (NYSE:NVO)

Bleakley Financial Group LLC trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 11.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,093 shares of the company’s stock after selling 9,086 shares during the quarter. Bleakley Financial Group LLC’s holdings in Novo Nordisk A/S were worth $6,029,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of NVO. Daiwa Securities Group Inc. bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $28,000. Capital Performance Advisors LLP bought a new stake in Novo Nordisk A/S in the third quarter worth $42,000. Albion Financial Group UT grew its stake in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after acquiring an additional 278 shares during the last quarter. Sound Income Strategies LLC increased its holdings in shares of Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after acquiring an additional 243 shares in the last quarter. Finally, Hager Investment Management Services LLC purchased a new position in shares of Novo Nordisk A/S in the 4th quarter worth about $46,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $85.83 on Thursday. The business has a 50-day simple moving average of $92.65 and a two-hundred day simple moving average of $112.19. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15. The stock has a market cap of $385.16 billion, a price-to-earnings ratio of 27.78, a PEG ratio of 0.93 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 35.03% and a return on equity of 86.32%. On average, analysts expect that Novo Nordisk A/S will post 3.16 EPS for the current year.

Analyst Upgrades and Downgrades

NVO has been the subject of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.